What is the difference between Amjevita and Humira?
Medically reviewed by Drugs.com Last updated on Sep 16, 2019.
Official Answerby Drugs.com
Amjevita (adalimumab-atto) is the first adalimumab (Humira) biosimilar approved by the FDA and, like Humira, is used in adults for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis; it is also approved for juvenile idiopathic arthritis (JIA) in children 4 years and older.
Amjevita is not approved to treat hidradenitis suppurativa, or uveitis, like Humira.
Amjevita is not approved as an interchangeable product at the pharmacy, meaning the pharmacist needs approval from the prescribing doctor to substitute Amjevita for Humira, if not specified on the prescription.
Like Humira, Amjevita is an anti-TNF-α monoclonal antibody that has the same amino acid sequence as adalimumab.
Common side effects include infections and injection site reactions. Amjevita is available in a prefilled syringe or autoinjector and is given by a subcutaneous injection.
For more information, see Comparing Amjevita vs Humira
Related Medical Questions
- What is the difference between Cyltezo and Humira?
- How many biosimilars have been approved in the United States?
- What are the new drugs for the treatment of plaque psoriasis?
- What are the new drugs for the treatment of rheumatoid arthritis (RA)?
- Can you take Humira with antibiotics?
- How much does Humira cost without insurance?
- How long can Humira be out of the fridge?
Related Support Groups
- Humira (88 questions, 334 members)
- Rheumatoid Arthritis (373 questions, 1197 members)
- Psoriatic Arthritis (41 questions, 234 members)
- Crohn's Disease (37 questions, 264 members)
- Ulcerative Colitis (30 questions, 167 members)
- Ankylosing Spondylitis (24 questions, 191 members)
- Plaque Psoriasis (18 questions, 62 members)
- Juvenile Idiopathic Arthritis